IAT0981 231
Alternative Names: IAT0981-231Latest Information Update: 08 Jun 2022
At a glance
- Originator SUNHO (China) BioPharmaceutical
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD8 positive T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 25 May 2022 SunHo (China) BioPharmaceutical plans a phase I trial in Cancer (Monotherapy, Late-stage disease, Combination therapy) in 2H of 2022
- 08 Apr 2022 Preclinical trials in Cancer in China (Parenteral)
- 08 Apr 2022 Pharmacodynamics and adverse events data from preclinical studies in Cancer released by SunHo (China) BioPharmaceutical and presented at American Association for Cancer Research